Trials / Completed
CompletedNCT02678260
Phase I Study of PDR001 in Patients With Advanced Malignancies.
A Phase-I Study of PDR001 Administered to Japanese Patients With Advanced Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to characterize the safety, tolerability, Pharmacokinetics (PK), and antitumor activity of PDR001 administered intravenous (i.v.) as a single agent to Japanese patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PDR001 | PDR001 is a high-affinity, ligand-blocking, humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1. |
Timeline
- Start date
- 2016-02-19
- Primary completion
- 2017-09-01
- Completion
- 2017-09-01
- First posted
- 2016-02-09
- Last updated
- 2018-06-08
Locations
3 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02678260. Inclusion in this directory is not an endorsement.